Crosswalk: Who Pays and Who Profits on Exa-cel, Per the 2022 Filings

Here's the concrete reader question in late 2022: CRISPR Therapeutics and Vertex have a gene-editing therapy moving toward regulators — so when it earns money, who actually keeps it? The answer is buried in the collaboration terms, and the filings spell it out.

In its Form 10-Q filed November 1, 2022, CRISPR Therapeutics describes its lead product candidate, CTX001 — now known as exagamglogene autotemcel, or exa-cel — a therapy for inherited blood disorders developed under its collaboration with Vertex. The economics are not a footnote; they are the whole question of how much this candidate is worth to each company.

Strip away the press release and the structure is this: the two companies restructured their arrangement so that Vertex leads. The filing record describes Vertex holding the right to control development and commercialization of exa-cel. In plain terms, the partner that was once a co-equal collaborator is now the one steering the program and taking the larger share — which means the value that flows to CRISPR Therapeutics is a negotiated slice, not the whole pie.

This is the crosswalk that matters: the science (an ex vivo CRISPR edit of a patient's own blood stem cells) is CRISPR Therapeutics' to be proud of, but the filing shows the money is increasingly Vertex's to direct. A reader who only knows the company name might assume CRISPR Therapeutics captures the upside of its namesake therapy. The disclosure says the split is more complicated.

Be precise about what is and isn't settled. As of this 2022 10-Q, exa-cel is still a candidate — the document calls it investigational. The economics being described are the terms that will govern if and when it is approved and sold. The contract is real now; the revenue is contingent.

The EdgarBeast evidence index, which surfaces and normalizes SEC filings, lets you read both partners' descriptions of the same deal and see who controls what. For exa-cel in late 2022, the filings point one way: Vertex leads, CRISPR Therapeutics shares — and that split is the real economics behind the science.